Transcript Highlights:

• Those include novating contract agreements, easements, transferring insurance, addressing indemnification

Summary: The Senate Transportation Committee met, took roll, and heard introductory remarks from members about their districts and transportation priorities, with several senators noting congestion and mobility challenges in their regions. The committee then received a presentation from the Florida Transportation Commission on its oversight role for FDOT, including annual and quarterly performance reviews, review of the five-year work program, and monitoring of tolling and transit authorities. Members asked whether the commission gets involved in project prioritization; the answer was no, because it is statutorily limited to high-level oversight rather than day-to-day project decisions. The committee next heard two reports related to transportation disadvantaged and paratransit services. FDOT’s Melissa Smith described the statewide Transportation Disadvantaged program, its governance structure, service models, and challenges such as fragmented administration, cost, inconsistent reporting, and rural service limitations. She outlined recommendations including better use of technology, regional partnerships, improved training, and alternative delivery models like microtransit and TNC partnerships. A University of South Florida researcher, Martin Katala, discussed best practices for paratransit and demand-response service, emphasizing route optimization software, dynamic dispatching, service standards, vendor accountability, and the use of TNCs and mobility management to improve efficiency and reduce travel times. A later presentation from UF’s I-Street program focused on emerging technologies for transit, including in-cabin monitoring, automatic restraints, accessible booking and tracking tools, and the need for statewide safety standards and better driver interfaces. Finally, FDOT Secretary Jared Perdue and District 5 Secretary John Tyler provided an update on the transition of SunRail local entities. They explained the differences among commuter rail, intercity rail, and light rail, and said SunRail’s financial transition to local partners was completed on January 1, with operational transition to follow over up to three years. They contrasted that with Tri-Rail, where FDOT still funds operations and discussions about a future transition are ongoing. Members asked about the differences between SunRail, Tri-Rail, Amtrak, and Brightline, and the presenters explained that commuter rail serves regional daily commuters while intercity rail connects regions. The committee concluded without taking any formal votes or other legislative action.

Transcript Highlights:

• If you look at fiscal year 24 actual under land acquisitions and easements, just under $3 million.
• ><02:05:09.119> and under land acquis acquisitions and under land acquis acquisitions and easements
• <02:05:11.199> We<02:05:11.440> had easements just under 3 million.
• We had easements just under 3 million.

Keywords: 1191, senate, all

Transcript Highlights:

• You were required to get prescription filled through the mail prescription filled through the mail prescription
• And let me state prescriptions. And let me state prescriptions.
• and for prescription prescriptions and for prescription prescriptions and for prescription medication
• prescription medicine was prescription prescription medicine was prescription prescription medicine
• drugs. prescription drugs. prescription drugs.

Bills: SCR 13, SCR 24, SB 1, SB 12, SB 15, SB 17, SB 24, SB 57, SB 65, SB 213, SB 371, SB 372, SB 378, SB 379, SB 388, SB 400, SB 402, SB 427, SB 495, SB 499, SB 502, SB 509, SB 535, SB 583, SB 610, SB 621, SB 650, SB 706, SB 740, SB 840, SB 854, SB 856, SB 875, SB 893, SB 918, SB 925, SB 974, SB 995, SB 1006, SB 1018, SB 1025, SB 1061, SB 1073, SB 1106, SB 1121, SB 1194, SB 1252, SB 1253, SB 1268, SB 1300, SB 1343, SB 1362, SB 1447, SJR 36, SJR 12, SJR 57, SCR 25, SCR 22, SCR 12, SCR 24, SCR 8, SB 565, SB 372, SB 765, SB 62, SB 666, SB 707, SB 888, SB 687, SB 847, SB 1248, SB 740, SB 14, SB 1006, SB 504, SB 925, SB 1121, SB 995, SB 857, SB 305, SB 296, SB 284, SB 815, SB 1379, SB 1300, SB 1497, SB 1499, SB 1498, SB 1061, SB 65, SB 241, SB 304, SB 402, SB 499, SB 621, SB 974, SB 1023, SB 1024, SB 1025, SB 1106, SB 686, SB 112, SB 371, SB 204, SB 400, SB 609, SB 1447, SB 670, SB 502, SB 427, SB 850, SB 854, SB 413, SB 1555, SB 1362, SB 1346, SB 1033, SB 1220, SB 1073, SB 810, SB 987, SB 1539, SB 893, SB 447, SB 875, SB 406, SB 509, SB 985, SB 965, SB 1119, SB 1505, SB 24, SB 57, SB 1194, SB 1253, SB 1215, SB 1532, SB 1268, SB 1302, SB 856, SB 650, SB 583, SB 673, SB 840, SB 213, SB 681, SB 1172, SB 1252, SB 378, SB 610, SB 918, SB 1343, SB 608, SB 487, SB 955, SB 957, SB 988, SB 990, SB 1019, SB 1021, SB 1120, SB 251, SB 958, SB 535, SB 761, SB 1, SB 541, SB 315, SB 379, SB 1018, SB 1737, SB 266, SB 1415, SB 57, SB 499, SB 974, SB 1025, SB 1061, SB 1268, SR 302, SR 303, SR 304, SR 305, SB 30, SB 1333, SB 1666, SB 30, SB 1333, SB 1666

Keywords: water rights, treaty compliance, Rio Grande, agriculture, drought, international water, Texas water supply, Texas, Israel, trade, investment, partnership, economic ties, technological innovation, bilateral relations, appropriations, budget, state funding, education, healthcare

Transcript Highlights:

• <00:04:08.360> drug statute and the the prescription drug statute and the the prescription
• executive director of the prescription executive director of the prescription drug<00:10:48.440>
• <00:11:16.200> drug Hampshire prescription drug Hampshire prescription drug affordability<
• with the governor on this prescription with the governor on this prescription drug<00:13:56.560>
• <01:06:33.400> drugs<01:06:33.680> more to make prescription drugs more to make prescription

Keywords: 928, house, all

Summary: The working session focused on the New Hampshire Prescription Drug Affordability Board’s budget request and its recent work. Early discussion centered on a technical question about a statutory dedicated fund for donations: members asked why the budget did not show a line item for accepting donations, and DHHS CFO Nathan White explained that the statute already authorizes the fund, but because no revenue has been received yet, it does not appear in the budget. He said any future donations would go through the normal process under RSA 14:30-a, with fiscal committee and Governor and Council approval and a memo to the Department of Revenue Administration. The chair clarified that the account was not a prerequisite to soliciting donations, and White said the fund would supplement, not replace, General Fund support. Kirk Williamson, the board’s executive director, then presented the board’s mission and budget. He said the governor’s budget provides about $256,500 in the first year and slightly more in the second, all General Funds, and that the board had distributed a technical amendment to continue the executive director position. He described the board’s role as analyzing prescription drug costs, identifying savings opportunities, monitoring market trends, promoting transparency, and making recommendations to the legislature and public payers. He also emphasized that the board operates publicly, with live-streamed meetings and a stakeholder advisory council that includes unions, state agencies, Medicaid, corrections, higher education, and other stakeholders. A major topic was the board’s estimate of $6 million in potential savings, based on Medicare’s newly negotiated prices for 10 drugs. Williamson explained that the board used those federal negotiated prices as a benchmark to estimate what New Hampshire public payers might be missing by not having similar leverage, and said the board is trying to build evidence for future recommendations rather than directly setting prices. Members asked how those potential savings could become actual savings, and Williamson said the board is sharing findings through its advisory council and feedback loops, though it has not yet sent a formal recommendation letter to specific purchasers. He also discussed the difference between pharmacy-benefit spending, which relies heavily on PBM-negotiated rebates, and medical-benefit spending, which is administered differently and is being added to the board’s next report. Williamson highlighted other work, including a model on Humira and a pending legislative effort to improve biosimilar competition, plus a proposed state-backed pharmacy savings card that would be no cost to the state and could save users about $240 per prescription based on Connecticut’s experience. No votes were taken during the session.

Transcript Highlights:

• They also control 100% of the Medicare prescriptions in Massachusetts.
• Just three PBMs now manage 80% of the prescription drug market.
• Just three PBMs now manage 80% of the prescription drug market.
• So they're losing $50 per prescription.
• Multiply that by 300 prescriptions a day, and if they fill 300 prescriptions, that's $15,000 a day.

Keywords: 995, all

Summary: The committee held a lengthy hearing on a large docket of pharmacy and drug-pricing bills, with most testimony focused on PBM reform, 340B drug discount program protections, specialty medication access, and medication adherence. Chair James Murphy and Senator Paul Feeney opened the hearing and took testimony from legislators, patient advocates, pharmacists, health center leaders, industry representatives, and policy groups. Several speakers described delays, denials, high out-of-pocket costs, and pharmacy closures tied to PBM practices, while others emphasized the importance of community health centers and independent pharmacies in serving patients. On the 340B program, supporters including Senator Eldridge, Senator Payano, Community Care Cooperative, Fenway Health, the Massachusetts League of Community Health Centers, and several community health center leaders argued that bills such as H. 1107 and S. 819 would stop discriminatory PBM and manufacturer practices, preserve contract pharmacy access, and protect safety-net providers that say they reinvest savings into care, pharmacy expansion, interpreter services, behavioral health, and other services. Opponents including PhRMA, the Community Liver Alliance, and a public policy analyst argued the program lacks transparency and accountability, has grown beyond its original purpose, and may benefit large hospitals and for-profit entities more than low-income patients. They urged more reporting and oversight rather than expanding protections. On PBM reform, testimony supported bills including H. 1157, H. 1234, S. 724, S. 831, and related measures that would require rebate pass-through, ban spread pricing, limit steering to PBM-owned pharmacies, and improve reimbursement for community pharmacies. Independent pharmacists and patients said current PBM practices raise costs, create administrative burdens, and threaten access to local pharmacies. PCMA, representing PBMs, opposed the reforms, arguing PBMs lower costs, that plan sponsors choose to contract with them, and that the Health Policy Commission and CHIA should complete their ongoing study before new mandates are adopted. The committee also heard support for H. 1322 and S. 734 on specialty medications, and for H. 781 and H. 1305 on medication synchronization to improve adherence. No votes or formal actions were taken during the hearing.

Transcript Highlights:

• Well, here in Texas, you need a prescription to get it. Yes, ma'am.
• and they were refusing to fulfill those prescriptions.
• That it's right now is a prescription-only medication.
• Let me talk about a couple of prescription medications.
• A patient needs to see a doctor prior to prescription.

Bills: HB25, HB48, HB149, HB254, HB26, HB192, HCR3, HCR4, HCR5, HCR6, HCR8, HCR14, HCR16, HR1, HR2, HR3, HR4, HR6, HR7, HR8, HR9, HR12, HR11, HR13, HR14, HR15, HR16, HR20, HR22, HR23, HR24, HR25, HR26, HR27, HR28, HR29, HR30, HR31, HR32, HR33, HR45, HR48, HR49, HR51, HR52, HR55, HR56, HR57, HR59, HR60, HR61, HR62, HR63, HR64, HR65, HR66, HR70, HR71, HR72, HR74, HCR2, HCR7, HR10, HR21, HR35, HR36, HR37, HR38, HR39, HR40, HR42, HR43, HR44, HR46, HR47, HR50, HR53, HR54, HR67, HR69, HR75, HCR 5, HCR 6, HCR 8, HCR 14, HCR 16, HR 1, HR 3, HR 4, HR 6, HR 7, HR 8, HR 9, HR 12, HR 11, HR 13, HR 14, HR 15, HR 16, HR 20, HR 22, HR 23, HR 24, HR 25, HR 26, HR 27, HR 28, HR 29, HR 30, HR 31, HR 32, HR 33, HR 45, HR 48, HR 49, HR 51, HR 52, HR 55, HR 56, HR 57, HR 59, HR 60, HR 61, HR 62, HR 63, HR 64, HR 65, HR 66, HR 70, HR 71, HR 72, HR 74, HCR 7, HR 10, HR 21, HR 35, HR 36, HR 37, HR 38, HR 39, HR 40, HR 42, HR 43, HR 44, HR 46, HR 47, HR 50, HR 53, HR 54, HR 67, HR 69, HB 25, HB 48, HB 149, HB 254, HB 26, HB 192

Keywords: ivermectin, pharmacist authority, prescription-free, healthcare regulation, patient access, HB 48, Texas alert notification systems, emergency alerts, public warning systems, alert fatigue, notification fatigue, Texas Division of Emergency Management, Department of Public Safety, DPS alerts, emergency management, State of Texas Emergency Assistance Registry, STEAR, disaster notifications, weather alerts, Amber Alert

Transcript Highlights:

• This bill does not add anything to the cost of a prescription.
• It only defines how a prescription must be.
• These bills impose a $10.64 fee on every prescription filled. $10.64 fee on every prescription filled
• Last year, they filled over 80% of the prescriptions. States.
• By law, you can't fill the prescription unless the pharmacist fills it. the prescription unless the pharmacist

Keywords: 923, senate, all

Transcript Highlights:

• one prescription if the expectation is one prescription per<01:19:51.280> month<01:19:51.600>
• :05.480> prescription, for an opioid prescription, for an opioid prescription, one<01:20:07.040
• Uh in the case of prescriptions.
• <01:21:26.680> are who need an opioid prescription are who need an opioid prescription are
• prescription for any reason statewide. prescription for any reason statewide.

Keywords: 1189, house, all

Summary: The committee met on May 29 and approved the draft minutes. DHHS Commissioner Weaver then opened the department update by asking Medicaid Director Henry Litman to brief members on federal and state Medicaid changes, and later turned to DHHS Chief Operating Officer David Weathers for an update on data governance. Members also asked that acronyms be spelled out in future materials and requested a follow-up on the federal Medicaid rule once it is published. Litman reviewed several federal Medicaid provisions tied to HR 1/"OBBA" and related state implementation issues. He said the first major change would be restrictions on certain non-citizens’ Medicaid coverage, affecting about 400 people in New Hampshire, with notices likely 30 to 60 days before the effective date. He also discussed new work requirements/community engagement rules, saying New Hampshire is on track to implement them and will likely need a state plan amendment rather than an 1115 waiver. Other changes included shorter retroactive coverage periods, a new state option for certain community-based services with an estimated $740,000 in implementation support, a freeze and phased-down reduction in the Medicaid enhancement tax beginning in state fiscal year 2029, and limits on directed payments to hospitals after a grandfathering period. He also noted that Medicaid enrollment has fallen from pandemic-era levels, with about 167,000 people covered as of May 1, and that the department is working with CMS on child premiums and other cost-sharing changes approved in HB 2. Committee members asked how the department could plan for the 2029 changes given the number of elections before then, and Litman said federal rules may be adjusted over time as states and stakeholders raise concerns. He emphasized planning for the worst while hoping for the best, and said rural health care transformation funding would help the state prepare. In the second presentation, Weathers explained that data governance is now embedded in DHHS operations to control access, manage reporting, and respond to risk. He defined it as managing what data is collected, how it is used, who can access it, and what laws apply, and said DHHS has moved from governance as a committee to governance as an operational process. He described privacy impact assessments for new systems going into production, monthly privacy and security training, and ongoing review of access controls and data-sharing rules.

Transcript Highlights:

• You can access it without a prescription? Ms.
• Wu: It is not approved for prescription dispensing Mr.
• Oliverson: A prescription-only medication, yes sir.
• To say pharmacists shall fill prescriptions?
• Let me talk about a couple prescription medicines.

Bills: HB25, HB48, HB149, HB254, HB26, HB192

Keywords: ivermectin, pharmacist authority, prescription-free, healthcare regulation, patient access, HB 48, Texas alert notification systems, emergency alerts, public warning systems, alert fatigue, notification fatigue, Texas Division of Emergency Management, Department of Public Safety, DPS alerts, emergency management, State of Texas Emergency Assistance Registry, STEAR, disaster notifications, weather alerts, Amber Alert

Transcript Highlights:

• When you fill a prescription, you set the price based on the cost to do business and a fair... ...and
• And today, in a world of electronic prescriptions, the drugstore pays for the electronic prescriptions
• We both were diagnosed pretty young and have dealt with prescription costs and prescription accessibility
• in on time, and make... ...get my prescriptions in on time.
• He and I knew each other, and he asked me would I fill those prescriptions for him.

Keywords: 923, senate, all

Transcript Highlights:

• We manage approximately 40 easements on properties and buildings.
• We sit on their review committees and then also manage a lot of their easements that come with those
• We manage approximately 40 easements on properties and buildings.
• We manage approximately 40 easements on properties and buildings.
• We sit on their review committees and then also manage a lot of their easements that come with those

Keywords: 928, house, all

Summary: New Hampshire Housing Finance Authority officials, led by Executive Director Rob Dapice, briefed legislators on the agency’s structure and funding. They explained that the authority is created by state law but is not a state agency, its debt is not state debt, and it is governed by a board appointed by the governor and approved by the Executive Council. The discussion focused on the Affordable Housing Fund and the lead paint hazard remediation fund, including how state appropriations and federal resources are combined to finance affordable rental housing and lead abatement work. Dapice said the Affordable Housing Fund is used as gap financing for multifamily affordable housing projects, typically alongside federal tax credits and tax-exempt bonds, and that state dollars leverage roughly 2:1 to 10:1 in additional federal and private investment, averaging about 4:1. He said the fund has received historic appropriations in recent budgets, including $30 million over the last two biennial budgets and an annual $5 million set-aside from the real estate transfer tax. He also said the fund is usually structured as 0% interest, deferred loans rather than grants, with repayments returning to the fund if projects generate cash flow. Members asked about rents, oversight, staffing, revenues, and whether the programs had added positions. Dapice said affordability restrictions generally last 30 to 99 years, rents are tied to income limits and capped so tenants pay no more than 30% of income, and compliance staff inspect properties regularly to verify income eligibility and rent limits. He said the organization has about 130 to 135 employees, down from about 145, with no new positions added because of the appropriations. He estimated total revenues at roughly $300 million, with administrative budget around $22 million, much of it pass-through grant money. On lead paint remediation, he said the state first appropriated $6 million in 2019, plus $1 million in ARPA funds, and that the program has cleared more than 500 units. He said the federal grant program is not annual or predictable, with a recent award of about $7.75 million, and that the maximum federal grant per unit is $177,000, typically paired with up to $100,000 in state loan support. He also noted that the program can address homes before a child is poisoned if lead hazards are identified, but that cases involving an already exposed child are a higher priority. No votes or formal actions were taken.

Transcript Highlights:

• What we're doing here with this amendment is we're trying to be more prescriptive with the language in
• When we did conservation easements, if it was $1.8 million taken off the rolls, it was $1.8 million.

Keywords: 999, senate, all

Transcript Highlights:

• Prescription drug costs are health care's biggest open secret.
• Prescription drug costs are health care's biggest open secret.
• Another who regularly crowds funds on social media to cover prescription costs.
• manufacturing and distribution of prescription medications.
• I repeat, they make more money as prescription drug costs rise.

Keywords: 995, all

Summary: The Joint Committee on Health Care Financing held a public hearing on a broad set of health care bills focused on cost, market oversight, pharmaceutical access, transparency, hospital closures, and pharmacy access. Chairs John Lawn and Cindy Friedman opened by emphasizing recent health care reforms and the need for further action on the drug supply chain, PBMs, private equity, and affordability. The committee heard testimony on several measures, including a Betsy Lehman Center bill to make technical changes and create a permanent trust account for federal and private funding, and bills on hospital profits and fairness, hospital closures and health planning, pharmacy deserts, and health care market oversight and pharmaceutical access. No votes were taken during the hearing. On the hospital profits bill, physicians and labor advocates strongly supported capping hospital CEO compensation at 50 times the lowest-paid worker, requiring greater financial transparency, and directing penalties from high-margin public hospitals into a Medicaid reimbursement fund. Testifiers argued that executive pay is excessive while frontline staff and safety-net services are under strain. Committee members raised concerns about unintended consequences, including whether hospitals might shift workers to contract status or lose executive talent, and whether the bill would actually direct money to the safety net. Supporters responded that the measure is one piece of a larger effort and that the bill’s Medicaid reimbursement provisions would help underserved hospitals. Testimony on market oversight and pharmaceutical access centered on rising health care and drug costs, PBM practices, and the proposal to give the Health Policy Commission authority to set upper payment limits for certain drugs. Consumer advocates, disability advocates, an independent pharmacist, the Attorney General’s office, and others supported stronger oversight, citing premium increases, affordability problems, and the impact of high drug prices on patients and community pharmacies. Pharma and some industry witnesses opposed parts of the bill, warning that upper payment limits could disrupt access, create legal issues, and fail to address the broader supply chain. The committee also heard support for stronger hospital closure notice and public hearing requirements, and for a pharmacy deserts bill aimed at identifying and addressing closures like the one in Roxbury that affected thousands of patients.

Transcript Highlights:

• Robinson: Would prescriptions now that are already there be grandfathered in, or does this take it all
• Robinson: Would prescriptions now that are already there be grandfathered in, or does this take it all
• BECAUSE OF THE BENEFITS OF THE STATE   387 HEALTH INSURANCE INCLUDING THE PRESCRIPTIONS.
• THAT PARTICULAR PORTION WOULD BE PRESCRIPTION   391 and it concerns me, and it concerns me
• THAT ARE COVERED MAJORITY OF THE   402 prescriptions that women who deal with any type of

Summary: The State Administration Budget Subcommittee met to consider four conforming committee bills tied to the proposed 2026-27 House General Appropriations Act. Rep. Maggard presented PCB SAB 26-04, the annual retirement bill, which updates Florida Retirement System contribution rates based on the annual actuarial study and was said to produce a $31.7 million state savings. He also presented PCB SAB 26-02, which addresses collective bargaining impasses for state employees by tying resolution to spending decisions in the appropriations act or implementing legislation. Both bills drew brief questions, mainly from Rep. Gantt, and both passed favorably on roll call. Rep. Miller presented PCB SAB 26-03, which reorganizes state audit functions and creates the Florida Accountability Office, consolidating legislative audit work into four divisions and adding whistleblower protections and reporting requirements. Rep. Gantt asked whether the bill changed the use of outside auditors and whether it had a fiscal impact; Miller said the work would be absorbed within existing resources and that the Legislature would retain responsibility. A taxpayer witness supported the bill and urged stronger local-government audit standards and broader whistleblower coverage. The bill passed favorably. Rep. Abbott presented PCB SAB 26-01, a broader appropriations conforming bill focused on the State Employee Health Insurance Trust Fund, prescription drug formulary changes, a health insurance assessment on agencies and vacant positions, the $3 traffic violation surcharge for the State Law Enforcement Radio System, Capitol complex space management, and changes to the Office of Supplier Diversity. Much of the discussion centered on whether a closed formulary would make medications harder to obtain, with Abbott saying prior authorization would still allow access and that the change was needed to control costs and protect the trust fund. Rep. Gantt and Rep. Robinson raised concerns about employee health benefits and the repeal of supplier diversity provisions, arguing the committee lacked data on the impact to minority- and women-owned businesses; Abbott said the changes would still allow small businesses to compete and that the bill was intended to save money and modernize procurement. PCB SAB 26-01 also passed favorably, and the meeting adjourned after all agenda items were reported out.

Transcript Highlights:

• I'm the executive director for the Missouri Prescription Drug Monitoring Program.
• And it's a pattern: the patient starts getting a prescription for Xanax.
• They will not be checking for making a decision related to the prescription.
• Because any prescription is going to come back to you ultimately, right? Yes.
• So they are either bedbound. ...to have prescriptions to function.

Summary: The Joint Committee on Administrative Rules met to consider a Missouri Prescription Drug Monitoring Program rule proposal after the Department of Natural Resources withdrew its items. The hearing focused on 1 CSR 60-1.010, which would expand delegate-level PDMP access to additional licensed behavioral health professionals, including licensed clinical social workers, licensed master social workers, marital and family therapists, professional counselors, and psychologists, while also correcting prior rule language involving medical assistants and clinical nurse specialists. Testimony from the PDMP executive director and supporters from Compass Health and the Department of Mental Health argued the change would improve care coordination, medication reconciliation, and safety in multidisciplinary behavioral health settings, especially CCBHCs. They said access would remain limited to licensed professionals working under a prescriber/dispenser relationship, with individual logins and penalties for misuse. Opponents and some committee members raised concerns that the rule would expand access beyond the original statutory framework without legislative change, could be used beyond treatment purposes, and should instead be addressed through statute rather than rulemaking. After public testimony, the committee debated whether the proposal exceeded statutory authority and whether the expansion was too substantive for rulemaking alone. A motion was made to disapprove the rule on grounds including lack of statutory authority, conflict with state law, and arbitrariness. The motion passed by a roll call vote of 7-1, and the committee disapproved Rule 1 CSR 60-1.010 before adjourning.

Transcript Highlights:

• You had to go see and get a prescription for this if you wanted to do that.
• You had to go see and get a prescription for this if you wanted to do that.
• You had to go see and get a prescription for this if you wanted to do that.
• You had to go see and get a prescription for this if you wanted to do that.
• This can be prescription through an MD.

Keywords: 1183, house

Summary: House File 4493 would authorize pharmacists to initiate, prescribe, administer, and dispense certain drugs for opioid use disorder, especially buprenorphine/Suboxone. Representative Baker said the bill is intended to save lives by giving people immediate access to treatment at the moment they seek help, rather than making them wait for a doctor’s appointment or navigate more cumbersome methadone access. He emphasized that pharmacists are widely accessible, including in greater Minnesota, and that optional training would support safe prescribing. Representative Bierman spoke in strong support, calling the measure a life-or-death step forward for people with substance use disorder and noting that many people do not receive treatment when they need it. He said he initially had concerns but Baker listened to his suggested changes and worked with him and bill drafters, which helped address those concerns. Bierman also referenced the ongoing fentanyl crisis and encouraged members to learn more from displays honoring overdose victims. Baker closed by sharing personal remarks about losing his son to addiction and describing how limited treatment options were at that time. He said the new federal change allowing pharmacist training makes the bill timely and urged members to support it. After discussion, the House took a roll call vote and passed the bill 134-0, with the title agreed to.

Transcript Highlights:

• purchase outpatient prescription purchase outpatient prescription medications<00:07:12.919> at
• <00:10:34.640> and their ability to fill prescriptions and their ability to fill prescriptions
• We've written almost 5,000 prescriptions in fiscal 2024 at...
• We've written almost 5,000 prescriptions in fiscal 2024 at...
• have provided over 4,500 prescriptions have provided over 4,500 prescriptions to<00:21:16.919>

Keywords: 00:00 Introductions 02:46 Roll Call 03:35 Discussion on SB 14 46:13 Vote on SB 14 48:07 Discussion on SB 17 50:38 Vote on SB 17, 958, all

Summary: The Senate Standing Committee on Health Services opened with the chair welcoming several new members and outlining session rules: hearings would start and end on time, the committee would limit the number of bills heard each meeting, prioritize bills heard during the interim, and generally avoid using the consent calendar except in extreme circumstances. The committee then briefly considered administrative regulations, which were treated as approved if members had no questions. The main item was Senate Bill 14, a measure addressing the 340B drug discount program. The chair said the bill had already passed the Senate in a prior session and had been heard in interim, so he did not present it again. He described the bill as prohibiting drug manufacturers from discriminating against 340B covered entities by refusing 340B pricing when the same drug is offered at that price in the state. He also said the committee would not debate the federal 340B program itself, but would hear testimony on the bill. Hospital leaders and Kentucky Hospital Association representatives testified in support, arguing that 340B savings are essential to rural hospitals, oncology services, transportation support, chronic care, addiction recovery, and new service lines such as chemotherapy and hepatitis treatment. They said the program helps keep care close to home and that manufacturer restrictions on contract pharmacies have reduced access and cost hospitals millions. Opponents from BIO Kentucky and the National Alliance of Healthcare Purchaser Coalitions argued the bill would expand federal law beyond Congress’s intent, create administrative burdens, and not lower patient out-of-pocket costs. The chair repeatedly pressed opponents to address why Kentucky should be denied the same 340B pricing available in other states. No vote on the bill was taken in the portion provided.

Transcript Highlights:

• I'm the executive director for the Missouri Prescription Drug Monitoring Program.
• And it's a pattern: the patient starts getting a prescription for Xanax.
• These patients, but these are not people who have prescriptive authority.
• They will not be checking for making a decision related to the prescription.
• Because any prescription is going to come back to you ultimately, right? Yes.

Keywords: 959, house, all

Transcript Highlights:

• Yes, veterinarians can write prescriptions to individual people.
• <00:20:37.640> So, prescriptions to individual people.
• So, prescriptions to individual people.
• And I understand I think prescription.
• prescription? prescription?

Keywords: 958, all

Summary: The committee first reviewed several Fish and Wildlife regulations. Staff explained amendments to 301 KAR 2:176, 4:112, and 6:030, including updating wildlife control tag language, creating an impoundment agent program for seized wildlife, and clarifying boating safety rules. A member raised a concern about boat wakes near docks, and staff said the commission had recently voted on related changes that were not yet included because the regulation had been filed earlier; those changes would have to come back later. The committee approved the staff amendments without objection. The Board of Veterinary Examiners then presented 201 KAR 16:767, which would require veterinary managers to be physically present during business hours and limit them to five registered facilities. Board representatives said they had tried to meet with affected parties before the hearing but had not reached agreement. A representative for Kentucky Pet IQ argued the rule was written for full-service hospitals and would be impractical for short, limited-service clinics that only provide vaccinations, preventive care, and parasite testing. Members expressed concern about the rule’s impact on veterinary access in underserved areas, and the committee voted to defer the regulation until the next month so the parties could continue negotiating. The committee next considered Transportation Cabinet 601 KAR 9:120, the online insurance verification system, in both ordinary and emergency form. The chair said staff had identified conflicts with a bill passed the prior year and moved to find the regulations deficient. The motion passed on a roll call vote, with six ayes and two pass votes. The committee then found ordinary ABC regulations 804 KAR 12:020 and 12:030 deficient as well, again by six ayes and two pass votes, after noting that the emergency versions had already been found deficient the previous month. Finally, the committee reviewed Cabinet for Health and Family Services 902 KAR 55:110, which would require veterinarians to report dispensed controlled substances to KASPER while exempting administered medications. OIG staff said the rule was meant to align regulation with statute, which includes veterinarians as prescribers, and emphasized that the reporting duty applies to prescriptions, not administration to animals. Some members supported the change as a needed anti-diversion measure, while others worried about implementation burdens and timing. After discussion, the committee found the regulation deficient by a 6-2 vote. The meeting then moved into full review of 922 KAR 1:565, a Department for Community Based Services rule implementing kinship care provisions from Senate Bill 151; staff said it was needed for implementation once funding is available, but a member criticized the two-year delay and the inclusion of language conditioning implementation on funding. A public witness from the Kinship Families Coalition argued the rule should not shift the 120-day application window in a way that could affect federal funding eligibility and urged the committee to reject the regulation as written.

Transcript Highlights:

• About a tenth goes to prescription drug spending.
• With prescription drugs, it's the same drug.
• drug spending has been... been, on average, prescription drug spending has been, or prescription drug
• We are expecting 2024 data any minute, but it does show prescription drugs, retail prescription drugs
• So I'm not here to say prescription drugs are bad.

Keywords: 1184, house, all